These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 28956845

  • 1. Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives.
    Wang L, Li P, Li B, Wang Y, Li J, Song L.
    Molecules; 2017 Sep 28; 22(10):. PubMed ID: 28956845
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J, Wan S, Wang G, Zhang T, Li Z, Tian Y, Yu Y, Wu X, Zhang J.
    Eur J Med Chem; 2016 Aug 08; 118():276-89. PubMed ID: 27132165
    [Abstract] [Full Text] [Related]

  • 3. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, Zhao Y, Zhang H, Qi C.
    Eur J Med Chem; 2017 Sep 29; 138():669-688. PubMed ID: 28711702
    [Abstract] [Full Text] [Related]

  • 4. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X, Lv Y, Liu P, Li Z, Hu L, Zeng C, Yang L.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1571-1575. PubMed ID: 26879314
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.
    El-Azab AS, Al-Omar MA, Abdel-Aziz AA, Abdel-Aziz NI, el-Sayed MA, Aleisa AM, Sayed-Ahmed MM, Abdel-Hamide SG.
    Eur J Med Chem; 2010 Sep 15; 45(9):4188-98. PubMed ID: 20599299
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y, Zou W, Peng L, Yang Z, Tang Q, Chen M, Jia S, Zhang H, Lan Z, Zheng P, Zhu W.
    Eur J Med Chem; 2018 Jun 25; 154():29-43. PubMed ID: 29775935
    [Abstract] [Full Text] [Related]

  • 7. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 8. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Chen L, Zhang Y, Liu J, Wang W, Li X, Zhao L, Wang W, Li B.
    Eur J Med Chem; 2017 Sep 29; 138():689-697. PubMed ID: 28711703
    [Abstract] [Full Text] [Related]

  • 9. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W, Ren Y, Zhang Z, Sun H, Ma Y, Yan B.
    Bioorg Med Chem; 2018 May 01; 26(8):1740-1750. PubMed ID: 29523467
    [Abstract] [Full Text] [Related]

  • 10. Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors.
    Wang Z, Wu X, Wang L, Zhang J, Liu J, Song Z, Tang Z.
    Bioorg Med Chem Lett; 2016 Jun 01; 26(11):2589-93. PubMed ID: 27118497
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y, Wang C, Xu S, Lan Z, Li W, Han J, Zhou Y, Zheng P, Zhu W.
    Bioorg Med Chem; 2017 Jun 15; 25(12):3148-3157. PubMed ID: 28428040
    [Abstract] [Full Text] [Related]

  • 12. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Zhang Y, Chen L, Xu H, Li X, Zhao L, Wang W, Li B, Zhang X.
    Eur J Med Chem; 2018 Mar 10; 147():77-89. PubMed ID: 29421573
    [Abstract] [Full Text] [Related]

  • 13. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
    Ahmed MF, Magdy N.
    Anticancer Agents Med Chem; 2017 Mar 10; 17(6):832-838. PubMed ID: 27671305
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
    Jin H, Wu BX, Zheng Q, Hu CH, Tang XZ, Zhang W, Rao GW.
    Future Med Chem; 2021 Apr 10; 13(7):601-612. PubMed ID: 33685233
    [Abstract] [Full Text] [Related]

  • 15. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM, Abou-Seri SM, Eldehna WM, Ismail NSM, Elgazwi SM, Ghabbour HA, Ahmed MS, Halaweish FT, Abou El Ella DA.
    Eur J Med Chem; 2018 Jul 15; 155():782-796. PubMed ID: 30047410
    [Abstract] [Full Text] [Related]

  • 16. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P, Chu J, Li Y, Wang Y, He Y, Qi C, Chang J.
    Bioorg Med Chem; 2019 Oct 15; 27(20):114938. PubMed ID: 31488358
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
    Lu L, Zhao TT, Liu TB, Sun WX, Xu C, Li DD, Zhu HL.
    Chem Pharm Bull (Tokyo); 2016 Nov 01; 64(11):1570-1575. PubMed ID: 27568484
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C, Xu S, Peng L, Zhang B, Zhang H, Hu Y, Zheng P, Zhu W.
    J Enzyme Inhib Med Chem; 2019 Dec 01; 34(1):203-217. PubMed ID: 30835140
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
    Ding HW, Deng CL, Li DD, Liu DD, Chai SM, Wang W, Zhang Y, Chen K, Li X, Wang J, Song SJ, Song HR.
    Eur J Med Chem; 2018 Feb 25; 146():460-470. PubMed ID: 29407971
    [Abstract] [Full Text] [Related]

  • 20. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS, Elshihawy HE, Said MM, Abouzid KA.
    Chem Pharm Bull (Tokyo); 2014 Feb 25; 62(5):454-66. PubMed ID: 24789927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.